Operating Segments (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Segment reporting
Total revenues	$ 228,640	$ 214,824	$ 416,703	$ 362,417
Loss from operations	(3,395,296)	(2,988,659)	(7,587,682)	(5,222,266)
Amortization and depreciation	8,512	8,840	16,744	17,739
Other (Expense) Income, Net	(146,399)	226,849	(303,034)	97,978
Share-based compensation	71,670	80,621	149,941	175,426
Identifiable Assets	21,312,454		$ 21,312,454		$ 26,869,927
Number of operating segments | segment			2
Operating Segments [Member] | Specialized BioTherapeutics [Member]
Segment reporting
Loss from operations	(2,000,350)	(1,720,566)	$ (3,540,078)	(2,832,974)
Amortization and depreciation	2,783	1,862	5,397	3,761
Other (Expense) Income, Net	68,509	41,001	123,588	125,635
Share-based compensation	28,343	28,731	56,847	58,310
Identifiable Assets	167,524		167,524		128,645
Operating Segments [Member] | Public Health Solutions [Member]
Segment reporting
Total revenues	228,640	214,824	416,703	362,417
Loss from operations	(1,002)	(231,954)	(121,623)	(362,735)
Amortization and depreciation	463	311	899	627
Share-based compensation	1,054	7,189	2,108	13,484
Identifiable Assets	330,545		330,545		146,296
Corporate, Non-Segment [Member]
Segment reporting
Loss from operations	(1,393,944)	(1,036,139)	(3,925,981)	(2,026,557)
Amortization and depreciation	5,266	6,667	10,448	13,351
Other (Expense) Income, Net	(214,908)	185,848	(426,622)	(27,657)
Share-based compensation	42,273	$ 44,701	90,986	$ 103,632
Identifiable Assets	$ 20,814,385		$ 20,814,385		$ 26,594,986